LNA-mediated microRNA silencing in non-human primates
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
microRNAs (miRNAs) are small regulatory RNAs that are important in development and disease and therefore represent a potential new class of targets for therapeutic intervention. Despite recent progress in silencing of miRNAs in rodents, the development of effective and safe approaches for sequence-specific antagonism of miRNAs in vivo remains a significant scientific and therapeutic challenge. Moreover, there are no reports of miRNA antagonism in primates. Here we show that the simple systemic delivery of a unconjugated, PBS-formulated locked-nucleic-acid-modified oligonucleotide (LNA-antimiR) effectively antagonizes the liver-expressed miR-122 in non-human primates. Acute administration by intravenous injections of 3 or 10 mg kg(-1) LNA-antimiR to African green monkeys resulted in uptake of the LNA-antimiR in the cytoplasm of primate hepatocytes and formation of stable heteroduplexes between the LNA-antimiR and miR-122. This was accompanied by depletion of mature miR-122 and dose-dependent lowering of plasma cholesterol. Efficient silencing of miR-122 was achieved in primates by three doses of 10 mg kg(-1) LNA-antimiR, leading to a long-lasting and reversible decrease in total plasma cholesterol without any evidence for LNA-associated toxicities or histopathological changes in the study animals. Our findings demonstrate the utility of systemically administered LNA-antimiRs in exploring miRNA function in rodents and primates, and support the potential of these compounds as a…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, some reports have shown that an anti-microRNA antisense oligonucleotide efficiently blocked the function of the microRNA, thereby alleviating diseases in rodents and nonhuman primates (29,30).”
From ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK–RSK pathway (2014) · cites this paper as [29]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766
Cited by
Items 901–1,000 of 1,004
microRNA regulation of lipoprotein metabolism
Goedeke, L., Aranda, J. F., & Fernández-Hernando, C. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000094 · Cited by 34
“In subsequent studies, efficient silencing of miR-122 was successfully achieved in the liver of nonhuman primates, which resulted in reduced plasma cholesterol without any signs of toxicity [8].”
BackgroundEstrabaud, E., Lapalus, M., Broët, P., Appourchaux, K., Muynck, S. D., Lada, O., Martinot-Peignoux, M., Bièche, I., Valla, D., Bédossa, P., et al. (2014) · Journal of Virology · doi:10.1128/jvi.00016-14 · Cited by 29
“Moreover, miR-122 expression is critical for HCV replication (24, 25, 41).”
BackgroundMicroRNA and Epigenetics: Diagnostic and Therapeutic Opportunities
Monroig-Bosque, P. D. C., & Călin, G. A. (2013) · Current Pathobiology Reports · doi:10.1007/s40139-013-0008-9 · Cited by 37
MicroRNAs as potential therapeutics for treating spinal cord injury.
Yan, H., Hong, P., Jiang, M. H., & Li, H. (2012) · PubMed Central · doi:10.3969/j.issn.1673-5374.2012.17.011 · Cited by 31
“Subsequently, Elmén et al [49] antagonized liver specific miRNA, miR-122, in both mouse and African green monkey, and reduced blood cholesterol level efficiently using synthetic locked-nucleic-acid-modified oligonucleotide (LNA-antimiR).”
BackgroundTargeting microRNAs in neurons: Tools and perspectives
Ruberti, F., Barbato, C., & Cogoni, C. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.10.031 · Cited by 39
“Studies in non-human primates have shown that the delivery of LNAantimiR122 effectively depletes miR-122 in the liver (Elmén et al., 2008) and improves HCV-induced liver pathology (Lanford et al., 2010).”
Molecular bioengineering of functional nucleic acids
Du, Z., Wu, X., Dang, Y., Wu, Q., Fu, T., He, L., Wang, X., Mou, S., Fang, X., Qu, F., et al. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00361-y · Cited by 38
Lee, D.-Y., Yang, T.-L., Huang, Y.-H., Lee, C.-I., Chen, L.-J., Shih, Y.-T., Wei, S.-Y., Wang, W.-L., Wu, C.-C., & Chiu, J. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.02.010 · Cited by 28
Targeting non-coding RNA for the therapy of renal disease
Denby, L., & Baker, A. H. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.02.001 · Cited by 31
Rana, M., Balcioglu, M., Robertson, N., & Yigit, M. V. (2013) · The Analyst · doi:10.1039/c3an02066e · Cited by 32
MicroRNA-based therapy in pain medicine: Current progress and future prospects
Tan, P.-H., Pao, Y.-Y., Cheng, J., Hung, K., & Liu, C. (2013) · Acta anaesthesiologica Taiwanica · doi:10.1016/j.aat.2013.11.001 · Cited by 34
MicroRNAs in Cardiovascular Health: From Order to Disorder
Karunakaran, D., & Rayner, K. J. (2013) · Endocrinology · doi:10.1210/en.2013-1299 · Cited by 26
“Elmén et al (85) quickly followed with miR-122 inhibition studies in African green monkeys, which both confirmed the role of miR-122 in regulating lipid metabolism in vivo as well as highlighted the therapeutic targetability of miRNAs in a model highly related to humans.”
BackgroundThe role of microRNAs in adipocyte differentiation
Zhang, R., Wang, D., Xia, Z., Chen, C., Cheng, P., Xie, H., & Luo, X. (2013) · Frontiers of Medicine · doi:10.1007/s11684-013-0252-8 · Cited by 28
“More recently, locked nucleic acids have been shown to be capable of potently antagonising miRNAs in vivo [82].”
Backgroundmi RNA in the Regulation of Ion Channel/Transporter Expression
Wang, Z. (2013) · Comprehensive physiology · doi:10.1002/cphy.c110002 · Cited by 31
MicroRNAs: Small but amazing, and their association with endothelin
von Brandenstein, M., Richter, C., & Fries, J. W. U. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.06.025 · Cited by 28
“For in vivo experiments in non-human primates (Elmen et al., 2008) or by injection into the hearts of mice (Patrick et al.”
BackgroundNovel Ser/Thr Protein Phosphatases in Cell Death Regulation
Sun, H., & Wang, Y. (2012) · Physiology · doi:10.1152/physiol.00034.2011 · Cited by 32
“Moreover, siRNA as a new type of molecular medicine has been exploited (26, 28, 68).”
AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?
van der Laan, L. J. W., Wang, Y., Tilanus, H. W., Janssen, H. L. A., & Pan, Q. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.548799 · Cited by 32
“Recently a so-called locked nucleic acid (LNA) antisense probe has been developed to effectively antagonize the function of miR-122 [90].”
BackgroundImpact of microRNAs for pathogenesis and treatment of hepatitis C virus infection.
Pfeffer, S., & Baumert, T. (2010) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2010.04.010 · Cited by 28
Cho, W. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.57 · Cited by 28
The impact of microRNAs on alterations of gene regulatory networks in allergic diseases
Baskara-Yhuellou, I., & Tost, J. (2020) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.11.006 · Cited by 31
Zhong, X., Coukos, G., & Zhang, L. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-427-8_21 · Cited by 69
“In addition, LNAs are compatible with RNase H cleavage and display high aqueous solubility and low toxicity in vivo (98).”
BackgroundEnvironmental regulation of valvulogenesis: implications for tissue engineering
Vis, P. W. R., Kluin, J., Sluijter, J. P. G., van Herwerden, L. A., & Bouten, C. V. C. (2010) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2010.05.032 · Cited by 29
“In addition, the therapeutic use of mimicking or inhibitory miRNA molecules is described after experiments in several animal models and pre-clinical investigations in primates [91,93].”
BackgroundMicroRNA-Related Strategies to Improve Cardiac Function in Heart Failure
Zhou, H., Tang, W., Yang, J., Peng, J., Guo, J., & Fan, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.773083 · Cited by 33
Role of microRNAs in Obesity-Related Kidney Disease
Caus, M., Eritja, À., & Božić, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111416 · Cited by 30
Liu, F., Shimakami, T., Murai, K., Shirasaki, T., Funaki, M., Honda, M., Murakami, S., Yi, M., Tang, H., & Kaneko, S. (2016) · Scientific Reports · doi:10.1038/srep30939 · Cited by 33
“It is one of the most developed anti-miR-122 therapies and has been intravenously administered to African green monkeys 20 .”
Insights on chiral, backbone modified peptide nucleic acids: Properties and biological activity
Moccia, M., Adamo, M. F. A., & Saviano, M. (2014) · Artificial DNA PNA & XNA · doi:10.1080/1949095x.2015.1107176 · Cited by 42
Gestational hypoxia and epigenetic programming of brain development disorders
Ma, Q., Xiong, F., & Zhang, L. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.010 · Cited by 35
Effects of hypoxic exercise training on microRNA expression and lipid metabolism in obese rat livers
Lu, Y., Jing, W., Feng, L.-S., Zhang, L., Xu, J.-F., You, T., & Zhao, J. (2014) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1400052 · Cited by 27
“Previous studies indicated that inhibition of miR-122 in vivo lowered serum TC and TG levels, and reduced gene expression of fatty acid and cholesterol syntheses (Krützfeldt et al., 2005; Esau et al., 2006; Elmén et al., 2008).”
BackgroundMicroRNAs in Liver Health and Disease
Hsu, S., & Ghoshal, K. (2013) · Current Pathobiology Reports · doi:10.1007/s40139-012-0005-4 · Cited by 32
Functional characteristics of a double negative feedback loop mediated by microRNAs
Cai, S., Zhou, P., & Liu, Z. (2013) · Cognitive Neurodynamics · doi:10.1007/s11571-012-9236-7 · Cited by 30
miRNA Targeting Drugs: The Next Blockbusters?
Schmidt, M. F. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6563-2_1 · Cited by 30
Targeted electro-delivery of oligonucleotides for RNA interference: siRNA and antimiR
Chabot, S., Teissié, J., & Golzio, M. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.002 · Cited by 35
Next-Generation MicroRNA Expression Profiling Technology
Fan, J.-B. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-427-8 · Cited by 27
MicroRNAs in B-cells: From normal differentiation to treatment of malignancies
Marques, S. C., Laursen, M. B., Bødker, J. S., Kjeldsen, M. K., Falgreen, S., Schmitz, A., Bøgsted, M., Johnsen, H. E., & Dybkaer, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3057 · Cited by 26
“It is involved in the cholesterol and lipid metabolism and also in hepatitis C virus replication [137].”
BackgroundOligonucleotide therapeutics and their chemical modification strategies for clinical applications
Kim, H., Kim, S., Lee, D., Lee, D., Yoon, J., & Lee, H. (2024) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-024-00669-8 · Cited by 33
“Santaris Pharma has developed an anti-miR with eight LNAs incorporated into a 15-mer PS DNA strand to improve the miR-122 inhibition efficiency (Elmén et al. 2008).”
Non-invasive diagnosis of endometriosis: Immunologic and genetic markers
Mahini, S. M., Younesi, M., Mortazavi, G., Samare‐Najaf, M., Azadbakht, M. K., & Jamali, N. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.11.013 · Cited by 37
He, Y., Cai, Y., Pai, P., Ren, X., & Xia, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.629611 · Cited by 26
Comparison of different chemically modified inhibitors of miR‐199b in vivo
Duygu, B., Juni, R., Ottaviani, L., Bitsch, N., Wit, J. B. M., de Windt, L. D., & Martins, P. A. D. C. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.11.013 · Cited by 26
Gomes, C. P. C., de Gonzalo‐Calvo, D., Toro, R., Fernandes, T. M., Theisen, D., Wang, D., Devaux, Y., & on behalf of the Cardiolinc™ network (2018) · Clinical Science · doi:10.1042/cs20171463 · Cited by 32
Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model
D'Abundo, L., Callegari, E., Bresin, A., Chillemi, A., Elamin, B., Guerriero, P., Huang, X., Saccenti, E., Hussein, E. M. A. A., Casciano, F., et al. (2017) · Oncogene · doi:10.1038/onc.2017.269 · Cited by 26
Managing Pancreatic Adenocarcinoma: A Special Focus in MicroRNA Gene Therapy
Passadouro, M., & Faneca, H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050718 · Cited by 32
“restriction is translated into exceptional hybridization affinity towards complementary single-stranded RNA molecule and its efficiency has been proven both in vitro and in vivo [111–113].”
BackgroundButt, A., Raja, A., Siddique, S., Khan, J., Shahid, M., Tayyab, G., Minhas, Z., Umar, M., Idrees, M., & Tong, Y. (2016) · Scientific Reports · doi:10.1038/srep21510 · Cited by 26
New treatment strategies for hepatitis C infection.
Ermiş, F., & Taşçı, E. Ş. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i17.2100 · Cited by 26
MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression
Kedmi, M., Sas‐Chen, A., & Yarden, Y. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4081578 · Cited by 27
“Since then, many delivery methods have been developed to systemically administer miRNA antisense oligonucleotides, which directly silence oncogenic miRNAs in tumors [95,96] or in the surrounding microenvironment [97].”
BackgroundTissue engineering and microRNAs: future perspectives in regenerative medicine
Gori, M., Trombetta, M., Santini, D., & Rainer, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1071349 · Cited by 34
“performed miRNA silencing in non-human primates by intravenous injection of a LNA-antimiR, obtaining an efficient silencing of the liver-expressed miR-122 without any evidence for LNA-associated toxicity [152].”
Mopidevi, B., Ponnala, M., & Kumar, A. (2013) · Physiological Genomics · doi:10.1152/physiolgenomics.00056.2013 · Cited by 26
“(5, 6) have shown that simple systemic delivery of a unconjugated, PBS-formulated LNA-anti-miR effectively antagonizes the liver-expressed miR-122 and lowers plasma cholesterol in African green monkeys.”
BackgroundPrinciples of miRNA-Target Regulation in Metazoan Models
Doxakis, E. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140816280 · Cited by 33
“Moreover, the therapeutic potential of miRs, already demonstrated in numerous studies, has further heightened the importance of research that seeks to understand both their mechanism of action and their biological significance [10–13].”
BackgroundTorres, A. G., Threlfall, R., & Gait, M. (2011) · Artificial DNA PNA & XNA · doi:10.4161/adna.17731 · Cited by 26
“and often now used as a tool for screening of anti-miRs.(26,30,32,33,37,38) Briefly, the reporter plasmid contains an exactly complementary miR-122 recognition site cloned into the 3'-untranslated region (UTR) of a Renilla luciferase (RLuc) gene, to bring Rluc under miR-122 control and a non-miR-122 regulated Firefly…”
MethodTargeting viral infection by microRNA inhibition
Roberts, A. P. E., & Jopling, C. (2010) · Genome Biology · doi:10.1186/gb-2010-11-1-201 · Cited by 26
“miR-122 levels was observed, coupled with derepression of endogenous targets and absence of signifi cant associated toxicity [14].”
Abrogation of esophageal carcinoma development in miR-31 knockout rats
Fong, L. Y. Y., Taccioli, C., Palamarchuk, A., Tagliazucchi, G. M., Jing, R., Smalley, K. J., Fan, S., Altemus, J., Fiehn, O., Huebner, K., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920333117 · Cited by 28
“Consistent with the long-lasting effect of antimiR (19), ZD:antimiR/5-wk esophagus, assessed 15 wk after antimiR dosing, showed an ∼70% decrease in miR-31 levels vs.”
BackgroundMeydan, C., Bekenstein, U., & Soreq, H. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00189 · Cited by 37
MicroRNA-mediated immune modulation as a therapeutic strategy in host-implant integration
Ong, S., Biswas, S. K., & Wong, S. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.013 · Cited by 26
miR‐122 decreases HCV entry into hepatocytes through binding to the 3′ UTR of OCLN mRNA
Sendi, H., Mehrab-Mohseni, M., Foureau, D. M., Ghosh, S., Walling, T., Steuerwald, N., Zamor, P. J., Kaplan, K., Jacobs, C., Ahrens, W., et al. (2015) · Liver international (Print) · doi:10.1111/liv.12698 · Cited by 25
Concise Review: New Frontiers in MicroRNA‐Based Tissue Regeneration
Frith, J., Porrello, E., & Cooper-White, J. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0032 · Cited by 25
Shi, B., & Abrams, M. (2013) · Journal of Histochemistry and Cytochemistry · doi:10.1369/0022155413484152 · Cited by 25
Quantitative proteomic strategies for the identification of microRNA targets
Li, C., Xiong, Q., Zhang, J., Ge, F., & Bi, L. (2012) · Espert Review of Proteomics · doi:10.1586/epr.12.49 · Cited by 25
Walker, A. K., & Näär, A. M. (2012) · Clinical Lipidology · doi:10.2217/clp.11.67 · Cited by 27
Engineering Small Interfering RNAs by Strategic Chemical Modification
Bramsen, J. B., & Kjems, J. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-119-6_5 · Cited by 34
The emerging role of miRNAs in Merkel cell carcinoma pathogenesis: Signaling pathway crosstalk
Rizk, N. I., Midan, H. M., Helal, G. K., Abulsoud, A. I., Elshaer, S. S., El-Husseiny, A. A., Fathi, D., Abdelmaksoud, N. M., Mageed, S. S. A., Elballal, M. S., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154771 · Cited by 27
Long Non-Coding RNAs, Cell Cycle, and Human Breast Cancer
Yin, Q., Ma, H., Bamunuarachchi, G., Zheng, X., & Ma, Y. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.074 · Cited by 29
Protective effect of LNA-anti-miR-132 therapy on liver fibrosis in mice
Momen‐Heravi, F., Catalano, D., Talis, A., Szabó, G., & Bala, S. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.05.007 · Cited by 30
“58,59 The inhibitors were injected 24 h prior to the CCl 4 regimen every week.”
Role of Noncoding RNA in Development of Nonalcoholic Fatty Liver Disease
Huang, R., Duan, X.-Y., Fan, J., Li, G.-M., & Wang, B.-C. (2019) · BioMed Research International · doi:10.1155/2019/8690592 · Cited by 24
miR-12 and miR-124 contribute to defined early phases of long-lasting and transient memory
Michely, J., Kraft, S., & Müller, U. (2017) · Scientific Reports · doi:10.1038/s41598-017-08486-w · Cited by 27
Definition and identification of small RNA sponges: Focus on miRNA sequestration
Migault, M., Donnou‐Fournet, E., Galibert, M., & Gilot, D. (2016) · Methods · doi:10.1016/j.ymeth.2016.11.012 · Cited by 31
MicroRNAs regulating apolipoprotein B-containing lipoprotein production
Zhou, L., Irani, S., Sirwi, A., & Hussain, M. M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.02.020 · Cited by 27
Strategies to Antagonize miRNA Functions In Vitro and In Vivo
Baigude, H., & Rana, T. M. (2014) · Nanomedicine · doi:10.2217/nnm.14.162 · Cited by 25
Nguyen, H. T., Tian, G., & Murph, M. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00071 · Cited by 27
Roadmap of miR-122-related clinical application from bench to bedside
Qiu, Z., & Dai, Y. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.867327 · Cited by 21
“Intravenous administration of 3 or 10 mg·kg LNA-antimiR to African green monkeys resulted in uptake of the LNA-antimiR in the cytoplasm of primate hepatocytes and formation of stable heteroduplexes between the LNA-antimiR and miR-122 [27].”
BackgroundThe importance of oncogenic transcription factors for oral cancer pathogenesis and treatment.
Yedida, G., Nagini, S., & Mishra, R. (2013) · Oral surgery, oral medicine, oral pathology and oral radiology · doi:10.1016/j.oooo.2013.02.010 · Cited by 24
Synthesis and properties of a bridged nucleic acid with a perhydro-1,2-oxazin-3-one ring.
Shrestha, A. R., Hari, Y., Yahara, A., Ōsawa, T., & Obika, S. (2011) · Journal of Organic Chemistry · doi:10.1021/jo201597e · Cited by 24
Sphingosine kinase 1 is a relevant molecular target in gastric cancer
Fuereder, T., Hoeflmayer, D., Jaeger-Lansky, A., Rasin-Streden, D., Strommer, S., Fisker, N., Bo, H.-S., Crevenna, R., & Wacheck, V. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328340bd95 · Cited by 24
Teferedegne, B., Murata, H., Quiñones, M., Peden, K., & Lewis, A. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014416 · Cited by 24
“Furthermore, profiling of miRNA expression can identify miRNAs that might serve as diagnostic and prognostic markers for different cancers as well as potential therapeutic targets [23,24,25,26,27].”
BackgroundMatching active site and substrate structures for an RNA editing reaction.
Pokharel, S., Jayalath, P., Maydanovych, O., Goodman, R., Wang, S. C., Tantillo, D., & Beal, P. (2009) · Journal of the American Chemical Society · doi:10.1021/ja9034076 · Cited by 24
Clinical potential of oligonucleotide-based therapeutics in the respiratory system
Moschos, S. A., Usher, L., & Lindsay, M. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.009 · Cited by 28
Chapter 5 MicroRNA-Mediated Gene Silencing
Pager, C. T., Wehner, K. A., Fuchs, G., & Sarnow, P. (2009) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(09)90005-9 · Cited by 21
Self-citationThe emerging role of miRNA-122 in infectious diseases: Mechanisms and potential biomarkers
Mirzaei, R., Karampoor, S., & Korotkova, N. L. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154725 · Cited by 27
Cell cycle associated miRNAs as target and therapeutics in lung cancer treatment
Fariha, A., Hami, I., Tonmoy, M. I. Q., Akter, S., Reza, H. A., Bahadur, N. M., Rahaman, M. M., & Hossain, M. S. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11081 · Cited by 27
The Key Role of microRNAs in Initiation and Progression of Hepatocellular Carcinoma
Khan, S., Zhang, D., Zhang, J.-Y., Hayat, M. K., Ren, J.-L., Nasir, S., Fawad, M., & Bai, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.950374 · Cited by 23
The Structure Basis of Phytochemicals as Metabolic Signals for Combating Obesity
Li, X., Zheng, L., Zhang, B., Deng, Z., & Luo, T. F. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.913883 · Cited by 33
Azuma, Y., Yokobori, T., Mogi, A., Yajima, T., Kosaka, T., Iijima, M., Shimizu, K., Shirabe, K., & Kuwano, H. (2020) · Surgery today (Print) · doi:10.1007/s00595-020-01976-x · Cited by 23
Ma, W., Chen, B., Zou, S., Jia, R., Cheng, H., Huang, J., Wang, H., He, X.-X., & Wang, K.-M. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b03420 · Cited by 23
MiRNA-Based Therapeutics in Oncology, Realities, and Challenges
Bălăcescu, O., Visan, S., Baldasici, O., Balacescu, L., Vlad, C., & Achimaș-Cadariu, P. (2018) · Antisense Therapy · doi:10.5772/intechopen.81847 · Cited by 23
He, L., Xie, M., Huang, J., Zhang, T., Shi, S., & Tang, T. (2016) · Plant Cell Reports · doi:10.1007/s00299-016-1933-y · Cited by 24
“…et al. 2005), mosquitoes (Bryant et al. 2010) and chickens (McGlinn et al. 2009) in vivo and have also been used as potential therapeutic agents targeting disease-associated miRNAs in mice (Krutzfeldt et al. 2005; Elmen et al. 2008a; Obad et al. 2011) and non-human primates (Elmen et al. 2008a).”
BackgroundMicroRNAs in Kidney Transplantation: Living up to Their Expectations?
van den Akker, E. K., Dor, F. J. M. F., IJzermans, J. N. M., & de Bruin, R. W. F. (2015) · Journal of Transplantation · doi:10.1155/2015/354826 · Cited by 20
“Because of their small size and stability, miRNAs could also be used as a therapeutic target by inactivating them using antagomirs or as a therapeutic agent as locked nucleic acids [48, 49].”
BackgroundMukai, H., Ozaki, D., Cui, Y., Kuboyama, T., Yamato-Nagata, H., Onoe, K., Takahashi, M., Wada, Y., Imanishi, T., Kodama, T., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.02.014 · Cited by 23
Analysis of microRNA expression profile induced by AICAR in mouse hepatocytes
Liu, J., Liu, W., Ying, H., Zhao, W., & Zhang, H. (2012) · Gene · doi:10.1016/j.gene.2012.09.118 · Cited by 21
MicroRNAs as components of regulatory networks controlling erythropoiesis
Azzouzi, I., Schmugge, M., & Speer, O. (2012) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2012.01774.x · Cited by 23
“Oligonucleotides used to inhibit the endogenous expression of miRNAs on cell cultures include antagomirs (25), 2¢-O-methyl-ribonucleotides (26) and LNA oligomers (27).”
BackgroundMicroRNAs in Cancer Translational Research
Cho, W. C. S. (2011) · Springer eBooks · doi:10.1007/978-94-007-0298-1 · Cited by 38
Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides
Yamamoto, T., Mukai, Y., Wada, F., Terada, C., Kayaba, Y., Oh, K., Yamayoshi, A., Obika, S., & Harada‐Shiba, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060817 · Cited by 24
Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs
Giovannini, C., Fornari, F., Piscaglia, F., & Gramantieri, L. (2021) · Cells · doi:10.3390/cells10030521 · Cited by 32
Humphries, B. A., Wang, Z., & Yang, C. (2020) · Cancers · doi:10.3390/cancers12051092 · Cited by 32
The Role of MicroRNAs in the Cardiac Response to Exercise
Liu, X., Platt, C., & Rosenzweig, A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029850 · Cited by 24
MicroRNAs in Renal Diseases: A Potential Novel Therapeutic Target
Petrillo, F., Iervolino, A., Zacchia, M., Simeoni, A., Masella, C., Capolongo, G., Perna, A., Capasso, G., & Trepiccione, F. (2017) · Kidney Diseases · doi:10.1159/000481730 · Cited by 22
MicroRNA-210 and its theranostic potential
Ren, C.-X., Leng, R., Fan, Y., Pan, H., Wu, C., & Ye, D. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2016.1206890 · Cited by 21
Capillary electrophoresis methods for microRNAs assays: A review
Ban, E., & Song, E. J. (2014) · Analytica Chimica Acta · doi:10.1016/j.aca.2014.08.034 · Cited by 24
Micromanaging hepatitis C virus.
Lieberman, J., & Sarnow, P. (2013) · New England Journal of Medicine · doi:10.1056/nejme1301348 · Cited by 22
“Nasopharyngitis 3 (33) 2 (22) 1 (11) 2 (22)”
Self-citationPEI-complexed LNA antiseeds as miRNA inhibitors
Thomas, M., Lange-Grünweller, K., Dayyoub, E., Bakowsky, U., Weirauch, U., Aigner, A., Hartmann, R. K., & Grünweller, A. (2012) · RNA Biology · doi:10.4161/rna.21165 · Cited by 22
“13,31 and 32) and low toxicity profiles in preclinical in vivo studies.(10) The rate constant k off of LNA/RNA hybrids is dramatically reduced(24,33) and therefore steric blockage of target nucleic acids is anticipated to be very efficient and persistent.”
BackgroundResultImplication of miRNA in the diagnosis and treatment of breast cancer
Castañeda, C. A., Agulló-Ortuño, M. T., Vara, J. Á. F., Cortés-Funes, H., Gómez, H., & Ciruelos, E. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.40 · Cited by 25
Astakhova, I. V., Ustinov, A., Korshun, V., & Wengel, J. (2011) · Bioconjugate chemistry · doi:10.1021/bc1005027 · Cited by 22
Ion trap collision-induced dissociation of locked nucleic acids
Huang, T.-Y., Kharlamova, A., & McLuckey, S. (2010) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2009.09.020 · Cited by 22
“Stable inhibition of miRNA functions in nonhuman primates by unconjugated LNA-anti-miR oligonucleotides has also been reported [23].”
BackgroundTranslational Implications of MicroRNAs in Clinical Diagnostics and Therapeutics
Sempere, L. F., & Kauppinen, S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00340-5 · Cited by 23
Self-citation
Metadata
- Authors
- Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., Gullans, S., Kearney, P., Sarnow, P., Straarup, E. M., & Kauppinen, S.
- Affiliations
- Stanford Medicine (US)
- University of Copenhagen (DK)
- Corresponding author
- Kauppinen, Sakari
- Venue
- Nature
- Published
- 2008-03-26
- Volume
- 452
- Issue
- 7189
- Pages
- 896-899
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142310248
- Cited by
- 1,589
- References
- 0
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 23 · 2023: 23 · 2022: 54 · 2021: 48 · 2020: 63 · 2019: 66 · 2018: 62 · 2017: 75 · 2016: 100 · 2015: 113 · 2014: 139 · 2013: 176 · 2012: 175
- FWCI
- 60.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- microRNA silencing, locked nucleic acid, miR-122, cholesterol lowering, vervet monkey, non-human primates, hepatocyte uptake, heteroduplex formation, serum cholesterol, siRNA, oligonucleotide toxicity, gene expression regulation, drug target validation
- MeSH terms
- Animals, Chlorocebus aethiops, Female, Mice, Inbred C57BL, Oligonucleotides, Gene Silencing, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.